ECC5004 (AZD5004) is a novel small-molecule GLP-1 RA for use as an oral therapy for chronic weight management and T2DM.
For research use only. We do not sell to patients.
| Name | ECC-5004 |
|---|---|
| Iupac Chemical Name | 3-[1-[2-[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-7-[(4R)-2,2-dimethyloxan-4-yl]indolizin-3-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one |
| Synonyms | ECC-5004 ; ECC 5004 ; ECC5004 ; AZD5004 ; AZD 5004 ; AZD-5004 |
| Molecular Formula | C48H46F2N10O5 |
| Molecular Weight | 880.36 |
| Smile | O=C1NC(C2(C3=C(C(N4CCC5=NN(C6=CC=C(F)C(C7CC7)=C6)C(N8C=CN(C9=C(F) C%10=C(N(C)N=C%10)C=C9)C8=O)=C5[C@@H]4C)=O)C=C%11C=C([C@H]%12CC(C)(C)OCC%12)C=CN3%11)CC2)=NO1 |
| InChiKey | JMKBTILBGROESC-LITSAYRRSA-N |
| InChi | InChI=1S/C48H46F2N10O5/c1-26-39-36(53-60(30-7-8-35(49)32(22-30)27-5-6-27)42(39)59-19-18-58(46(59)63)38-10-9-37-34(40(38)50)25-51-55(37)4)12-17-56(26)43(61)33-23-31-21-28(29-13-20-64-47(2,3)24-29)11-16-57(31)41(33)48(14-15-48)44-52-45(62)65-54-44/h7-11,16,18-19,21-23,25-27,29H,5-6,12-15,17,20,24H2,1-4H3,(H,52,54,62)/t26-,29+/m0/s1 |
| CAS Number | 2758659-09-3 |
| Related CAS | 2758659-09-3 |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | ≧98.0% |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO (DMSO : ≥ 100 mg/mL) |
| Handling | Refer to MSDS |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |